Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Alper TopalDepartment of Medical Oncology, Health Science University, Gulhane Research and Training Hospital, Ankara 06010, Turkey.ORCID 0000-0002-9679-9245
Goncagul AkdagDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey.ORCID 0000-0002-6221-0623
Sedat YildirimDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey.ORCID 0000-0002-2423-6902
Oguzcan KinikogluDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey.ORCID 0000-0001-5983-3291
Deniz IsikDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey.ORCID 0000-0003-4398-5148
Gizem YildirimDepartment of Medical Oncology, Health Science University, Gulhane Research and Training Hospital, Ankara 06010, Turkey.
Salih TunbekiciDivision of Medical Oncology, Departmant of Internal Medicine, Ege Universitiy, Izmir 35100, Turkey.
Fatih KusDepartment of Medical Oncology, Hacettepe University Oncology Institue, Ankara 06230, Turkey.ORCID 0000-0003-1650-154X
Aydın AcarbayDivision of Medical Oncology, Departmant of Internal Medicine, Istanbul Medeniyet University, Istanbul 34730, Turkey.
Murad GuliyevDivision of Medical Oncology, Departmant of Internal Medicine, Istanbul University-Cerrahpasa, Istanbul 34098, Turkey.ORCID 0000-0002-2981-8098
Nargiz MajidovaDepartment of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul 34854, Turkey.ORCID 0000-0002-2575-5819
Yasin KutluDepartment of Medical Oncology, Tokat State Hospital, Tokat 60000, Turkey.ORCID 0000-0003-2184-634X
Mustafa ErmanDepartment of Medical Oncology, Hacettepe University Oncology Institue, Ankara 06230, Turkey.ORCID 0000-0001-5884-4669
Hatice OdabasDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey.ORCID 0000-0002-5757-4705
Nedim TuranDepartment of Medical Oncology, Kartal Dr. Lütfi Kirdar City Hospital, Health Science University, Istanbul 34865, Turkey.ORCID 0000-0002-1140-8779
Nuri KaradurmusDepartment of Medical Oncology, Health Science University, Gulhane Research and Training Hospital, Ankara 06010, Turkey.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. · full record | OpenQuestion